Insiders Trades
Vita Life Sciences Limited.. Stock: price and insider trades · Australia
1 insider bought shares over the last 90 days, the latest filed 06 Oct 2026.
Vita Life Sciences Limited..: what insiders have been doing
Vita Life Sciences Limited. belongs to the Health Care sector. Filings by its managers are published through ASX. Over the twelve months to 18 October 2026, the company's managers filed 4 filings, from 2 insiders.
Purchases and sales both appear in the filings: 1 purchase (1 insider) and 3 sales (2 insiders, €107k). The totals do not cover 2 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a sale of €63k from Henry George Townsing, disclosed on 11 May 2026, or 0.072% of market capitalisation. Those buying include 1 senior executive.
The latest purchase is recent: it was published 11 days ago, on 6 October 2026. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 2,526 companies tracked on its exchange, the median is 3 filings; at 4 filings, this issuer sits above that mark. Our records for Vita Life Sciences Limited. go back to 2026, with 1 purchase and 3 sales on the open market in total.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Every figure here comes from the filings published by ASX and describes the past, not future prices; it is not investment advice.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
1 ops. · all time
Sell Volume
€107,132
3 ops. · all time
Who traded when
BuySaleHenry George Townsing2 sales
Unknown1 buy1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,503 of 24,148 companies
77.5
score / 100
Value73
Quality82
FCF yld11%
Earn yld7.0%
EV/EBITDA9.6x
ROE21%
Gross mgn61%
Net mgn11%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
A$2.76
Analyst consensus
Income statement
RevenueA$93.3M
Gross profitA$57M61% margin
EBITDAA$15.8M17% margin
Net incomeA$10.4M11.6% margin
Valuation
PER (trailing)13.8x
P/Book2.7x
Beta0.48
Balance sheet & cash
Market capA$149.3M
Total debtA$2.4M
Free Cash FlowA$15.9M
Debt / Equity4%
Profitability & ownership
ROE20.6%
ROA12.3%
% insiders76.7%
% institutions5.5%
Last declaration on 6 October 2026
Declarations4 total
29,947 shares@ A$2.41180.051% mcap41.4% of flowShareASXISIN AU000000VLS8ASX:2924-03095359-3A694325
40,753 shares@ A$2.50250.072% mcap58.6% of flowShareASXISIN AU000000VLS8ASX:2924-03088881-3A693088
4 of 4 declarations
About Vita Life Sciences Limited..
Vita Life Sciences Limited is a company focused on the health and pharmaceutical sector. It is listed on the Australian Securities Exchange (XASX).
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
